ANKRD30A

Summary

ANKRD30A (ankyrin repeat domain 30A, HGNC:17234) is a protein-coding gene on chromosome 10p11.21, encoding Ankyrin repeat domain-containing protein 30A (Q9BXX3).

This gene encodes a DNA-binding transcription factor that is uniquely expressed in mammary epithelium and the testis. Altered expression levels have been associated with breast cancer progression.

Source: NCBI Gene 91074 — RefSeq curated summary.

At a glance

• GWAS associations: 16
• Clinical variants (ClinVar): 204 total — 1 pathogenic
• MANE Select transcript: NM_052997

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17234
Approved symbol	ANKRD30A
Name	ankyrin repeat domain 30A
Location	10p11.21
Locus type	gene with protein product
Status	Approved
Aliases	NY-BR-1
Ensembl gene	ENSG00000148513
Ensembl biotype	protein_coding
OMIM	610856
Entrez	91074

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000361713, ENST00000374660, ENST00000475522, ENST00000602533, ENST00000696674

RefSeq mRNA: 1 — MANE Select: NM_052997 NM_052997

CCDS: CCDS7193

Canonical transcript exons

ENST00000361713 — 36 exons

Exon	Start	End
ENSE00000985684	37130205	37130378
ENSE00000985688	37141718	37142290
ENSE00000985713	37218980	37219897
ENSE00000993157	37232499	37232567
ENSE00001436047	37231461	37231680
ENSE00001685942	37158392	37158420
ENSE00001713818	37216181	37216394
ENSE00001721666	37133916	37134053
ENSE00001723869	37129893	37130007
ENSE00001726380	37199727	37199788
ENSE00001728990	37136607	37136671
ENSE00001776434	37144995	37145056
ENSE00001803357	37147370	37147457
ENSE00001805490	37217695	37217878
ENSE00002434878	37169652	37169724
ENSE00002438683	37152060	37152121
ENSE00002445565	37149651	37149679
ENSE00002455706	37132240	37132346
ENSE00002460902	37166605	37166695
ENSE00002468899	37193186	37193258
ENSE00002474410	37165094	37165155
ENSE00002474713	37158514	37158586
ENSE00002480718	37149777	37149849
ENSE00002492764	37153572	37153662
ENSE00002504017	37169530	37169558
ENSE00002504941	37197408	37197480
ENSE00002506216	37176157	37176218
ENSE00002511787	37162776	37162848
ENSE00002515500	37197281	37197309
ENSE00002518724	37173712	37173740
ENSE00002526904	37173839	37173911
ENSE00002529228	37201235	37201325
ENSE00002532697	37162649	37162677
ENSE00003560142	37189467	37189557
ENSE00003644489	37193064	37193092
ENSE00003893764	37125598	37126008

Expression profiles

Bgee: expression breadth broad, 69 present calls, max score 86.14.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0218 / max 12.6304, expressed in 6 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
104700	0.0218	6

Top tissues by expression

217 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
epithelium of mammary gland	UBERON:0003244	86.14	gold quality
mammary duct	UBERON:0001765	86.07	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.37	gold quality
thoracic mammary gland	UBERON:0005200	76.21	gold quality
mammary gland	UBERON:0001911	76.10	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	72.19	gold quality
sperm	CL:0000019	58.00	gold quality
testis	UBERON:0000473	55.29	gold quality
right testis	UBERON:0004534	54.64	gold quality
cardiac muscle of right atrium	UBERON:0003379	54.34	gold quality
left ventricle myocardium	UBERON:0006566	54.23	gold quality
kidney epithelium	UBERON:0004819	53.93	gold quality
epithelial cell of pancreas	CL:0000083	53.66	gold quality
upper arm skin	UBERON:0004263	53.52	gold quality
left testis	UBERON:0004533	53.46	gold quality
pancreatic ductal cell	CL:0002079	51.80	silver quality
myocardium	UBERON:0002349	50.25	gold quality
adult organism	UBERON:0007023	50.17	gold quality
nipple	UBERON:0002030	49.12	silver quality
deltoid	UBERON:0001476	48.22	gold quality
nasal cavity epithelium	UBERON:0005384	47.03	gold quality
buccal mucosa cell	CL:0002336	46.95	gold quality
ileal mucosa	UBERON:0000331	46.59	silver quality
tibialis anterior	UBERON:0001385	46.53	silver quality
quadriceps femoris	UBERON:0001377	46.39	gold quality
vastus lateralis	UBERON:0001379	45.40	gold quality
colonic epithelium	UBERON:0000397	45.16	gold quality
mucosa of transverse colon	UBERON:0004991	45.09	gold quality
layer of synovial tissue	UBERON:0007616	43.55	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	43.42	silver quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-MTAB-10885	yes	2819.22
E-MTAB-10855	yes	2375.54
E-CURD-7	yes	2261.49
E-ENAD-21	yes	2261.49
E-MTAB-9841	yes	1506.08
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ESR1

miRNA regulators (miRDB)

21 targeting ANKRD30A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7107-3P	99.93	66.73	627
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-1208	99.70	68.28	1533
HSA-MIR-519D-5P	99.41	69.30	2057
HSA-MIR-6878-3P	99.24	64.23	920
HSA-MIR-6744-3P	99.22	64.41	972
HSA-MIR-4757-5P	99.12	64.51	981
HSA-MIR-491-3P	98.88	68.86	1224
HSA-MIR-873-5P	98.84	66.90	1348
HSA-MIR-1301-3P	98.64	68.27	1071
HSA-MIR-5047	98.64	68.62	1035
HSA-MIR-3944-5P	98.50	67.55	997
HSA-MIR-654-3P	98.38	67.61	905
HSA-MIR-1914-5P	97.83	66.21	807
HSA-MIR-3663-5P	97.01	64.84	713

Literature-anchored findings (GeneRIF, showing 10)

• In this study we extended the expression analysis to various other normal and tumor tissues and found inconsistent expression of NY-BR-1 in normal prostate, but consistent NY-BR-1 mRNA expression in 32% of prostate cancers, but not in other tumor types (PMID:16335914)
• NY-BR-1 is a differentiation antigen of the breast, which is present in normal and tumorous mammary epithelium. (PMID:16675566)
• The strong expression of NY-BR-1 in breast tumors, its cytoplasmic and membrane localization and accessibility to an ectopically applied antibody now suggest to pursue NY-BR-1 as a potential target for antibody-based therapies in breast cancer patients. (PMID:17330232)
• testing demonstrates NY-BR-1 in a mostly focal fashion in the epithelia of ducts and acini of the mammary gland. In tumors, homogenous staining can be seen in almost all ductal carcinomas in situ and/or the intraductal component of invasive carcinomas. (PMID:17536312)
• We identified estrogen-response element (ERE)-like sequences nearby the NY-BR-1 promoter region, suggesting that NY-BR-1 expression might be regulated through estrogen receptors. (PMID:18041742)
• The exclusive expression of Cancer-testis antigens in tumor tissues as well as the frequent expression of NY-BR-1 could define new targets for specific breast cancer therapies. (PMID:23731661)
• Results revealed a significant difference in NY-BR-1 Ag expression between benign and malignant breast cancer patients (PMID:26415367)
• Over 2800 SNPs are recorded in the dbSNP and NHLBI Exome Sequencing Project (ESP) databases for the NY-BR-1 gene. (PMID:27863482)
• Authors found a high sensitivity for all the markers analyzed. Moreover, the expression of NY-BR-1 and GATA-3 seemed the most effective for labelling male breast cancer in primary and metastatic setting. (PMID:29116378)
• This observation was confirmed in four independent cohorts, GSE22138, GSE54467, GSE65904 and E-MTAB-4725. In addition, the melanoma score was independent of most clinically used indicators. (PMID:31786890)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:ch211-272n13.3	ENSDARG00000099768
drosophila_melanogaster	CG8679	FBGN0032934
drosophila_melanogaster	CG42391	FBGN0259737
caenorhabditis_elegans	lem-3	WBGENE00002276
caenorhabditis_elegans		WBGENE00019483
caenorhabditis_elegans		WBGENE00206377

Paralogs (7): ANKRD26 (ENSG00000107890), ANKRD30BL (ENSG00000163046), ANKRD18A (ENSG00000180071), ANKRD30B (ENSG00000180777), ANKRD62 (ENSG00000181626), ANKRD18B (ENSG00000230453), ANKRD20A1 (ENSG00000260691)

Protein

Protein identifiers

Ankyrin repeat domain-containing protein 30A — Q9BXX3 (reviewed: Q9BXX3)

Alternative names: Serologically defined breast cancer antigen NY-BR-1

All UniProt accessions (4): Q9BXX3, A0A8Q3WLF6, Q5W026, R4GNA2

UniProt curated annotations — full annotation on UniProt →

Tissue specificity. Mainly expressed in breast and testis. A very faint signal is detected in placenta. Also expressed in many breast cancer cells.

RefSeq proteins (1): NP_443723* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002110	Ankyrin_rpt	Repeat
IPR036770	Ankyrin_rpt-contain_sf	Homologous_superfamily
IPR039497	CC144C-like_CC_dom	Domain
IPR050657

Pfam: PF12796, PF14915

UniProt features (25 total): repeat 6, compositionally biased region 6, region of interest 4, sequence variant 4, coiled-coil region 2, sequence conflict 2, chain 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
6R2L	X-RAY DIFFRACTION	2.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BXX3-F1	56.16	0.14

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-9927418	Developmental Lineage of Mammary Gland Luminal Epithelial Cells
R-HSA-9927426	Developmental Lineage of Mammary Gland Alveolar Cells

MSigDB gene sets: 24 (showing top): ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP, chr10p11, CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP, SALL4_TARGET_GENES, MIR4659A_3P_MIR4659B_3P, MIR1305, MIR6875_3P, MIR519E_5P, MIR515_5P, MIR519D_5P, MIR491_3P, MIR654_3P, MEBARKI_HCC_PROGENITOR_WNT_DN, DESCARTES_FETAL_PLACENTA_SMOOTH_MUSCLE_CELLS

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (0):

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Developmental Lineages of the Mammary Gland	2

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1

Protein interactions and networks

STRING

1660 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ANKRD30A	MAP4	P27816	438
ANKRD30A	CD8A	P01732	433
ANKRD30A	CCNY	Q8ND76	423
ANKRD30A	SCGB2A2	Q13296	410
ANKRD30A	RANBP2	P49792	406
ANKRD30A	RNF225	M0QZC1	400
ANKRD30A	SCGB2A1	O75556	387
ANKRD30A	ASZ1	Q8WWH4	377
ANKRD30A	TPP2	P29144	348
ANKRD30A	POTEE	Q6S8J3	345
ANKRD30A	LGMN	Q99538	340
ANKRD30A	CTAG1A	P78358	339
ANKRD30A	LNPEP	Q9UIQ6	335
ANKRD30A	ANP32E	Q9BTT0	323
ANKRD30A	MAGEA1	P43355	320

IntAct

2 interactions, top by confidence:

A	B	Type	Score
ANKRD30A	SCLT1	psi-mi:“MI:0914”(association)	0.350

BioGRID (10): ANKRD30A (Affinity Capture-MS), SCLT1 (Affinity Capture-MS), RAB3IP (Affinity Capture-MS), ANKRD30B (Affinity Capture-MS), SPAG5 (Affinity Capture-MS), NPM1 (Cross-Linking-MS (XL-MS)), ANKRD30A (Cross-Linking-MS (XL-MS)), TFIP11 (Cross-Linking-MS (XL-MS)), EEA1 (Cross-Linking-MS (XL-MS)), ANKRD30A (Reconstituted Complex)

ESM2 similar proteins: A0A087WUL8, A0A0J9YWL9, A0A0U1RQI7, A0A1D9BZF0, A6NJU9, A6NKU9, A6NNC1, A6QL64, A8MRT5, B2SU53, B4DH59, B5DUH6, C9JG80, E5RHQ5, F8W0I5, P01068, P02895, P06916, P07907, P0DKL2, P0DPF3, P0DRJ4, P13208, P14417, P32072, P83060, Q26755, Q3BBV0, Q3BBV2, Q4ZJY7, Q4ZJZ0, Q4ZJZ1, Q4ZJZ3, Q5TAG4, Q5TI25, Q6P3W6, Q6RY98, Q7T3L1, Q86SG3, Q86T75

Diamond homologs: A0A0A6YYL3, A0JP26, A0PJZ0, A2A2Z9, A2RUR9, A5A3E0, A6NC57, A6NI47, A7E2S9, B2RU33, H3BUK9, P0CG38, P0CG39, Q3MJ40, Q4R3S3, Q4UJ75, Q5CZ79, Q5JPF3, Q5SQ80, Q5TYW2, Q5VUR7, Q6NSI1, Q6S545, Q6S5H5, Q6S8J3, Q6S8J7, Q811D2, Q86YR6, Q8IYA2, Q92527, Q9BXX2, Q9BXX3, Q9D504, Q9H560, Q9UPS8, Q8IVF6, A6QL64, Q8N2N9, Q8NF67, Q96IX9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

204 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	172
Likely benign	18
Benign	2

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
146088	GRCh38/hg38 10p11.22-11.1(chr10:31999920-38119681)x3	Pathogenic

SpliceAI

6159 predictions. Top by Δscore:

Variant	Effect	Δscore
10:37125967:G:GT	donor_gain	1.0000
10:37126006:GAG:G	donor_gain	1.0000
10:37130374:ACAAG:A	donor_loss	1.0000
10:37130375:CAAGG:C	donor_loss	1.0000
10:37130376:AAG:A	donor_loss	1.0000
10:37130377:AGGTA:A	donor_loss	1.0000
10:37130378:GG:G	donor_loss	1.0000
10:37130380:T:C	donor_loss	1.0000
10:37132330:GTTAA:G	donor_gain	1.0000
10:37132331:TTAAT:T	donor_gain	1.0000
10:37132334:A:AG	donor_gain	1.0000
10:37132334:A:G	donor_gain	1.0000
10:37133911:TTTA:T	acceptor_loss	1.0000
10:37133914:A:AG	acceptor_gain	1.0000
10:37133914:AGCAC:A	acceptor_loss	1.0000
10:37133915:G:GA	acceptor_gain	1.0000
10:37133915:GC:G	acceptor_gain	1.0000
10:37133915:GCA:G	acceptor_gain	1.0000
10:37133915:GCAC:G	acceptor_gain	1.0000
10:37133915:GCACA:G	acceptor_gain	1.0000
10:37134009:TG:T	donor_gain	1.0000
10:37134010:G:GT	donor_gain	1.0000
10:37134010:GG:G	donor_gain	1.0000
10:37134049:CATCA:C	donor_gain	1.0000
10:37134050:ATCA:A	donor_gain	1.0000
10:37134051:TCA:T	donor_gain	1.0000
10:37134052:CA:C	donor_gain	1.0000
10:37134052:CAG:C	donor_loss	1.0000
10:37134054:G:GA	donor_loss	1.0000
10:37134054:G:GG	donor_gain	1.0000

AlphaMissense

8973 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:37130205:G:C	A113P	0.993
10:37129914:T:G	C81W	0.992
10:37129997:C:A	P109H	0.991
10:37130242:T:C	L125P	0.991
10:37129912:T:C	C81R	0.990
10:37129946:T:C	L92P	0.990
10:37130304:G:C	A146P	0.990
10:37133932:G:C	A212P	0.990
10:37129893:G:C	R74S	0.989
10:37129893:G:T	R74S	0.989
10:37130274:G:C	D136H	0.989
10:37130275:A:T	D136V	0.989
10:37130341:T:C	L158P	0.989
10:37129913:G:A	C81Y	0.988
10:37133969:T:C	L224P	0.988
10:37125995:G:C	D70H	0.987
10:37125996:A:T	D70V	0.987
10:37129898:C:A	A76D	0.987
10:37125997:C:A	D70E	0.986
10:37125997:C:G	D70E	0.986
10:37134032:C:A	A245D	0.986
10:37129997:C:G	P109R	0.985
10:37130242:T:A	L125Q	0.985
10:37130305:C:A	A146D	0.985
10:37132304:T:C	L192P	0.985
10:37129909:G:C	A80P	0.984
10:37129978:G:C	D103H	0.984
10:37129979:A:T	D103V	0.984
10:37130276:T:A	D136E	0.984
10:37130276:T:G	D136E	0.984

dbSNP variants (sampled 300 via entrez): RS1000038813 (10:37156275 T>A,C), RS1000096137 (10:37242085 A>T), RS1000098746 (10:37249411 GTAAA>G), RS1000110521 (10:37209949 T>C), RS1000114372 (10:37165164 T>G), RS1000182594 (10:37232190 A>C), RS1000218031 (10:37212356 A>C,T), RS1000223793 (10:37221546 T>G), RS1000242244 (10:37225401 T>C), RS1000280693 (10:37255085 T>C), RS1000282833 (10:37243287 A>C,T), RS1000311248 (10:37239174 A>G), RS1000369798 (10:37261014 C>G,T), RS1000404309 (10:37239480 G>A), RS1000419741 (10:37218809 G>A)

Disease associations

OMIM: gene MIM:610856 | disease phenotypes: MIM:114480

GenCC curated gene-disease

Mondo (2): breast ductal adenocarcinoma (MONDO:0005590), hereditary breast carcinoma (MONDO:0016419)

Orphanet (1): Hereditary breast cancer (Orphanet:227535)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

16 associations (top):

Study	Trait	p-value
GCST000080_8	Hemostatic factors and hematological phenotypes	6.000000e-06
GCST000189_28	Protein quantitative trait loci	3.000000e-06
GCST000274_6	Metabolite levels	3.000000e-09
GCST001588_12	Periodontal microbiota	2.000000e-06
GCST002576_1	Epithelial ovarian cancer	3.000000e-08
GCST003097_42	Pediatric autoimmune diseases	8.000000e-11
GCST005024_84	Pursuit maintenance gain	2.000000e-06
GCST005288_2	Extrinsic epigenetic age acceleration	7.000000e-11
GCST006275_2	Vestibular neuritis	1.000000e-09
GCST006484_7	Type 2 diabetes	9.000000e-07
GCST012299_7	Schizophrenia, bipolar disorder or major depressive disorder x sex interaction (3df)	4.000000e-06
GCST012308_11	Schizophrenia	2.000000e-06
GCST012309_12	Schizophrenia	2.000000e-06
GCST012310_5	Schizophrenia x sex interaction	2.000000e-06
GCST012311_17	Schizophrenia x sex interaction	2.000000e-06
GCST012322_40	Triglyceride levels x SSRI defined daily dose interaction in schizophrenia or bipolar disorder	1.000000e-08

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0004527	mean corpuscular hemoglobin
EFO:0004614	apolipoprotein A 1 measurement
EFO:0008433	pursuit maintenance gain measurement
EFO:0000473	epigenetic status
EFO:0022597	aging
EFO:0008343	sex interaction measurement
EFO:0004530	triglyceride measurement
EFO:0005658	response to selective serotonin reuptake inhibitor

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390
C562840	Breast Cancer, Familial (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
pirinixic acid	decreases expression	1
bisphenol A	increases expression	1
butyraldehyde	decreases expression	1
2-palmitoylglycerol	increases expression	1
jinfukang	decreases expression	1
Air Pollutants	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Silicon Dioxide	decreases expression	1
Valproic Acid	increases methylation	1
Cyclosporine	decreases expression	1
Aflatoxin B1	increases methylation	1
Asbestos, Serpentine	decreases methylation	1
Asbestos, Crocidolite	decreases methylation	1
Asbestos, Amosite	decreases methylation	1
Okadaic Acid	decreases expression	1
Genistein	increases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A2HI	EO-NY	Cancer cell line	Female
CVCL_A2HJ	EO-NY/PX458/#1	Cancer cell line	Female
CVCL_D7K1	Ubigene A-549 ANKRD30A KO	Cancer cell line	Male

Clinical trials (associated diseases)

21 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery
NCT00040222	Not specified	COMPLETED	Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
NCT02557776	Not specified	COMPLETED	Written Genetic Counseling and Mutation Analysis of BRCA1 and BRCA2 to Patients With Breast Cancer
NCT03495544	Not specified	UNKNOWN	Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer
NCT03959267	Not specified	COMPLETED	Testing a Culturally Adapted Telephone Genetic Counseling Intervention
NCT04058418	Not specified	COMPLETED	Specialist Recommendation on FBC (Familial Breast Cancer) Chemoprevention Prescribing
NCT04125914	Not specified	ACTIVE_NOT_RECRUITING	Weight Management and Health Behavior Intervention in Lowering Cancer Risk for BRCA Positive and Lynch Syndrome Families
NCT04169542	Not specified	RECRUITING	Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
NCT04197856	Not specified	ACTIVE_NOT_RECRUITING	Direct Information to At-risk Relatives
NCT07292246	Not specified	RECRUITING	A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)
NCT07307664	Not specified	RECRUITING	Increasing Germline Genetic Testing for Patients With Cancer